{"classes":[{"categories":[{"measurements":[{"comment":"first OS event occurred after 24 months","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"100"},{"comment":"first OS event occurred after 24 months","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"description":"OS: The length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Panobinostat (LBH589): 20 mg by mouth three (3) times per week, every other week, of a 28-day schedule.\n\nPanobinostat: Maintenance therapy dosing as outlined in Cohorts A and B.","id":"OG000","title":"Cohort A: Maintenance Therapy"},{"description":"Panobinostat (LBH589): 10 mg by mouth daily for seven (7) days, every other week, of a 28-day schedule.\n\nPanobinostat: Maintenance therapy dosing as outlined in Cohorts A and B.","id":"OG001","title":"Cohort B: Maintenance Therapy"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"at 2 years","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}